Arista Options Turn Defensive as Stock Slides Into Q3 Print
Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish
Arista Networks enters its Q3 earnings report on November 3 with the stock down 21% over the past month to $164.14, and options traders markedly more cautious than they were four weeks ago.
The clearest shift is in options positioning. The put/call ratio has climbed to 0.9955, about 1.5 standard deviations above its 20-day average of 0.92. That is not yet at the 52-week peak of 1.05, but the direction has been consistent: put demand began accelerating in early October when the PCR was running below 0.86, and has barely paused since. The move reflects investors paying more for downside protection as the stock gave back a substantial portion of its earlier gains.
Short interest, by contrast, remains a non-story. Fewer than 1% of the free float is sold short, and that figure has fallen 8% over the past month even as the stock declined. Borrowing costs have risen 168% over 30 days to 1.19%, but from an exceptionally low base: at that level, borrowing remains cheap and availability is effectively unlimited. The selling pressure behind the recent slide is almost entirely from existing holders trimming, not from new short positions being established.
The fundamental debate centres on whether Arista's raised bar is achievable. Bulls point to management's 2026 revenue growth guidance of 27.7%, AI revenue guidance of $3.5 billion, deferred revenue of $6.2 billion, and operating margins near 46% to 47%, all supported by sustained hyperscaler demand from Microsoft and Meta. The concern from the other side is concentration. Two customers account for an outsized share of revenue, and any sign of capex restraint from either would hit Arista's numbers quickly. TD Cowen cut its target from $250 to $205 in mid-October while keeping a Buy rating, a sign that even supportive analysts are recalibrating after the stock's run from August lows. The mean analyst target of $243 implies roughly 48% upside from current levels, though that consensus was formed before the October slide fully played out. The P/E multiple has compressed by more than nine points over the past 30 days to 32.5x, a valuation reset that both reflects the price weakness and narrows the margin for a miss.
CEO-adjacent insider activity is also worth noting. CTO Kenneth Duda executed a cluster of sales on October 20 under a pre-arranged 10b5-1 plan, netting roughly $2.4 million across multiple transactions at prices between $177 and $183. The planned nature of the trades limits their signal value, but the 90-day net insider position is negative at around $183 million in net sales, consistent with a pattern of insiders monetising at higher prices through the year.
The Q3 print will test whether Arista's revenue and margin trajectory justifies the premium the Street had assigned it at its September highs, or whether the October de-rating reflected something the numbers will now confirm.
Stocks in this article
See the live data behind this article on ORTEX.
Open ANET on ORTEX →How this article was generated
- Generated
- 3 Nov 2026, 05:19
- Data as of
- 3 Nov 2026, 04:12
- Prompt version
- v1.0
- Data sources
- Short interestCost to borrowUtilizationOptions flowEarningsInstitutional positioningORTEX Alpha signalsRecent ORTEX notesAlt DataPrevious Mi Articles
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.